Last reviewed · How we verify
ASP1707 single dose of dose levels 1 -7
ASP1707 single dose of dose levels 1 -7 is a Small molecule drug developed by Astellas Pharma Europe B.V.. It is currently in Phase 1 development.
At a glance
| Generic name | ASP1707 single dose of dose levels 1 -7 |
|---|---|
| Sponsor | Astellas Pharma Europe B.V. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASP1707 single dose of dose levels 1 -7 CI brief — competitive landscape report
- ASP1707 single dose of dose levels 1 -7 updates RSS · CI watch RSS
- Astellas Pharma Europe B.V. portfolio CI
Frequently asked questions about ASP1707 single dose of dose levels 1 -7
What is ASP1707 single dose of dose levels 1 -7?
ASP1707 single dose of dose levels 1 -7 is a Small molecule drug developed by Astellas Pharma Europe B.V..
Who makes ASP1707 single dose of dose levels 1 -7?
ASP1707 single dose of dose levels 1 -7 is developed by Astellas Pharma Europe B.V. (see full Astellas Pharma Europe B.V. pipeline at /company/astellas-pharma-europe-b-v).
What development phase is ASP1707 single dose of dose levels 1 -7 in?
ASP1707 single dose of dose levels 1 -7 is in Phase 1.